Rilzabrutinib Plus Low-Dose Steroid Fails Pemphigus Trial Rilzabrutinib Plus Low-Dose Steroid Fails Pemphigus Trial

Rilzabrutinib did not meet primary or secondary endpoints in the phase 3 PEGASUS trial of patients with pemphigus vulgaris or foliaceus.Medscape Medical News

Source: Medscape Dermatology Headlines - April 3, 2024 Category: Dermatology Tags: Dermatology Source Type: news